(Q40544528)

21 September 2017

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate (English)

1 reference

21 September 2017

1 reference

A J Tipping

1

1 reference

21 September 2017

S Baluch

2

1 reference

21 September 2017

D J Barnes

3

1 reference

21 September 2017

D R Veach

4

1 reference

21 September 2017

B M Clarkson

5

1 reference

21 September 2017

W G Bornmann

6

1 reference

21 September 2017

F X Mahon

7

1 reference

21 September 2017

J M Goldman

8

1 reference

21 September 2017

J V Melo

9

1 reference

21 September 2017

1 August 2004

1 reference

21 September 2017

1 reference

21 September 2017

18

1 reference

21 September 2017

1352-1356

1 reference

21 September 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403416

21 September 2017

0 references

cites work

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

Cytogenetic and molecular mechanisms of resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

inferred from DOI database lookup

7 January 2021

based on heuristic

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403416

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403416

1 reference

Dimensions Publication ID

21 September 2017

0 references

1 reference